Background:Chikungunya virus(CHIKV)is an infectious agent that caused several outbreaks among different countries and affected approximately 1.3 million Indian populations.It is transmitted by Aedes mosquito–either A...Background:Chikungunya virus(CHIKV)is an infectious agent that caused several outbreaks among different countries and affected approximately 1.3 million Indian populations.It is transmitted by Aedes mosquito–either A.albopictus or A.aegypti.Generally,the clinical manifestations of CHIKV infection involve high-grade fever,joint pain,skin rashes,headache,and myalgia.The present study aims to investigate the relationship between the CHIKV virus load and clinical symptoms of the CHIKV infection so that better patient management can be done in the background of the CHIKV outbreak as there is no licensed anti-viral drug and approved vaccines available against CHIKV.Methods:CHIKV RTPCR positive samples(n=18)(Acute febrile patients having D.O.F≤7 days)were taken for the quantification of CHIKV viremia by Real-Time PCR.Clinical features of the febrile patients were recorded during the collection of blood samples.Results:The log mean virus load of 18 RT-PCR-positive samples was 1.3×10^(6) copies/mL(1.21×10^(3)–2.33×10^(8) copies/mL).Among the observed clinical features,the log mean virus load(CHIKV)of the patients without skin rash is higher than in the patients with skin rash(6.61 vs.5.5,P=0.0435).Conclusion:The conclusion of the study was that the patients with skin rashes had lower viral load and those without skin rashes had higher viral load.展开更多
Viral hepatitis remains a significant worldwide threat,in spite of the availability of several successful therapeutic and vaccination strategies.Complications associated with acute and chronic infections,such as liver...Viral hepatitis remains a significant worldwide threat,in spite of the availability of several successful therapeutic and vaccination strategies.Complications associated with acute and chronic infections,such as liver failure,cirrhosis and hepatocellular carcinoma,are the cause of considerable morbidity and mortality.Given the significant burden on the healthcare system caused by viral hepatitis,it is essential that novel,more effective therapeutics be developed.The present review attempts to summarize the current treatments against viral hepatitis,and provides an outline for upcoming,promising new therapeutics.Development of novel therapeutics requires an understanding of the viral life cycles and viral effectors in molecular detail.As such,this review also discusses virallyencoded effectors,found to be essential for virus survival and replication in the host milieu,which may be utilized as potential candidates for development of alternative therapies in the future.展开更多
文摘Background:Chikungunya virus(CHIKV)is an infectious agent that caused several outbreaks among different countries and affected approximately 1.3 million Indian populations.It is transmitted by Aedes mosquito–either A.albopictus or A.aegypti.Generally,the clinical manifestations of CHIKV infection involve high-grade fever,joint pain,skin rashes,headache,and myalgia.The present study aims to investigate the relationship between the CHIKV virus load and clinical symptoms of the CHIKV infection so that better patient management can be done in the background of the CHIKV outbreak as there is no licensed anti-viral drug and approved vaccines available against CHIKV.Methods:CHIKV RTPCR positive samples(n=18)(Acute febrile patients having D.O.F≤7 days)were taken for the quantification of CHIKV viremia by Real-Time PCR.Clinical features of the febrile patients were recorded during the collection of blood samples.Results:The log mean virus load of 18 RT-PCR-positive samples was 1.3×10^(6) copies/mL(1.21×10^(3)–2.33×10^(8) copies/mL).Among the observed clinical features,the log mean virus load(CHIKV)of the patients without skin rash is higher than in the patients with skin rash(6.61 vs.5.5,P=0.0435).Conclusion:The conclusion of the study was that the patients with skin rashes had lower viral load and those without skin rashes had higher viral load.
基金a grant from the Department of Biotechnology,India (BT/PR7439/MED/29/676/2012).D.D
文摘Viral hepatitis remains a significant worldwide threat,in spite of the availability of several successful therapeutic and vaccination strategies.Complications associated with acute and chronic infections,such as liver failure,cirrhosis and hepatocellular carcinoma,are the cause of considerable morbidity and mortality.Given the significant burden on the healthcare system caused by viral hepatitis,it is essential that novel,more effective therapeutics be developed.The present review attempts to summarize the current treatments against viral hepatitis,and provides an outline for upcoming,promising new therapeutics.Development of novel therapeutics requires an understanding of the viral life cycles and viral effectors in molecular detail.As such,this review also discusses virallyencoded effectors,found to be essential for virus survival and replication in the host milieu,which may be utilized as potential candidates for development of alternative therapies in the future.
